KCNA3 and multiple sclerosis: Based on these toxin–potassium channel interactions, a novel control technique of toxin–potassium channel recognition was developed [104], and used to rationally design a selective ADWX-1 peptide for treating the Kv1.3 channel-mediated multiple sclerosis [103,105,106].